PMID- 31828124 OWN - NLM STAT- MEDLINE DCOM- 20200427 LR - 20200427 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2019 DP - 2019 TI - Polydatin Inhibits Adipose Tissue Inflammation and Ameliorates Lipid Metabolism in High-Fat-Fed Mice. PG - 7196535 LID - 10.1155/2019/7196535 [doi] LID - 7196535 AB - Polydatin (PD), an active component of Chinese herbs, is reported to have many biological functions, such as cardioprotective actions, anti-inflammatory activities, and antitumor effects. In this study, we investigated the effects of PD on body weight control, glucose and lipid metabolic regulation, and anti-inflammation in a high-fat-diet- (HFD-) induced obese mice model. After treatment of PD (100 mg/kg/d for 4 weeks), HFD mice reduced body weight, retroperitoneal fat mass, and adipose cell sizes; significantly lowered serum total cholesterol triglyceride (TG) and low-density lipoprotein (LDL) levels; and increased high-density lipoprotein (HDL) levels compared with the HFD control mice. Further studies showed that PD downregulated the mRNA and protein expressions of peroxisome proliferator-activated receptor gamma (PPARgamma), a transcription factor involving in the regulation of adipocyte differentiation, in the retroperitoneal fat of HFD mice. Additionally, PD significantly upregulated the mRNA and protein expressions of leptin, an adipocyte-derived anorexic hormone that regulates food intake and energy expenditure, in the adipose tissues of HFD mice. Moreover, PD reduced the expression levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-alpha) in the retroperitoneal and epididymal tissues of HFD mice, suggesting that PD prevented adipose tissue inflammation. In conclusion, PD may serve as a pharmaceutic candidate for obesity-related lipid metabolism, anti-inflammation, and body weight loss. CI - Copyright (c) 2019 Li Zheng et al. FAU - Zheng, Li AU - Zheng L AUID- ORCID: 0000-0001-5360-4463 AD - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. FAU - Wu, Jiayuan AU - Wu J AD - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. FAU - Mo, Juanfen AU - Mo J AD - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. FAU - Guo, Li AU - Guo L AD - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. FAU - Wu, Xiaoyan AU - Wu X AD - Clinical Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. FAU - Bao, Yi AU - Bao Y AUID- ORCID: 0000-0001-7144-5849 AD - The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, China. LA - eng PT - Journal Article DEP - 20191115 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Glucosides) RN - 0 (PPAR gamma) RN - 0 (Stilbenes) RN - XM261C37CQ (polydatin) SB - IM MH - Adipose Tissue/*drug effects MH - Administration, Oral MH - Animals MH - *Diet, High-Fat MH - Energy Metabolism/drug effects MH - Glucosides/administration & dosage/*pharmacology MH - Inflammation/*metabolism MH - Lipid Metabolism/*drug effects MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Obese MH - PPAR gamma/metabolism MH - Stilbenes/administration & dosage/*pharmacology PMC - PMC6885157 COIS- The authors declare that there are no conflicts of interest regarding the publication of this article. EDAT- 2019/12/13 06:00 MHDA- 2020/04/28 06:00 PMCR- 2019/11/15 CRDT- 2019/12/13 06:00 PHST- 2019/08/19 00:00 [received] PHST- 2019/10/14 00:00 [revised] PHST- 2019/10/18 00:00 [accepted] PHST- 2019/12/13 06:00 [entrez] PHST- 2019/12/13 06:00 [pubmed] PHST- 2020/04/28 06:00 [medline] PHST- 2019/11/15 00:00 [pmc-release] AID - 10.1155/2019/7196535 [doi] PST - epublish SO - Biomed Res Int. 2019 Nov 15;2019:7196535. doi: 10.1155/2019/7196535. eCollection 2019.